Targeting Human C-Type Lectin-like Molecule-1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

(2013) C. Krupka et al.   BLOOD

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

(2013) G. S. Laszlo et al.   BLOOD

Antibody therapy for acute myeloid leukaemia

(2013) Robin E. Gasiorowski et al.   BRITISH JOURNAL OF HAEMATOLOGY

Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system

(2013) C Arndt et al.   LEUKEMIA

Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells

(2013) C Arndt et al.   LEUKEMIA

Bispecific small molecule-antibody conjugate targeting prostate cancer

(2013) C. H. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

(2012) R. B. Walter et al.   BLOOD

Clinical Experience with Gene Therapy and Bispecific Antibodies for T Cell-based Therapy of Cancer

(2012) Patrick A. Baeuerle et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Synthesis of Bispecific Antibodies using Genetically Encoded Unnatural Amino Acids

(2012) Chan Hyuk Kim et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

(2012) M Aigner et al.   LEUKEMIA

Monoclonal TCR-redirected tumor cell killing

(2012) Nathaniel Liddy et al.   NATURE MEDICINE

Leukemia Stemness Signatures Step toward the Clinic

(2011) Michael W. Becker et al.   Cell Stem Cell

Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up

(2011) Hanne Ø. Larsen et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Adding New Chemistries to the Genetic Code

(2010) Chang C. Liu et al.   Annual Review of Biochemistry

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

(2010) Yoshikane Kikushige et al.   Cell Stem Cell

Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells

(2010) Y. Saito et al.   Science Translational Medicine

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts

(2009) R. Le Dieu et al.   BLOOD

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

(2009) Liqing Jin et al.   Cell Stem Cell

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

(2009) X. Zhao et al.   HAEMATOLOGICA

C002 C-type lectin-like molecule-1 (CLL-1) and lineage infidelity marker expression as assessed by flow cytometry distinguishes normal and aberrant stem cells in myelodysplastic syndromes

(2009) T. Westers et al.   LEUKEMIA RESEARCH

Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3

(2008) M. Amann et al.   CANCER RESEARCH

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE